Cargando…

Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study

BACKGROUND: In the global REACH-2 study, ramucirumab significantly improved overall survival (OS) compared with placebo in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP). REACH-2 China study aimed to evaluate the efficacy and safety of ramucirumab in Chine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Guoliang, Bai, Yuxian, Yuan, Xianglin, Chen, Xiaomin, Gu, Shanzhi, Gu, Kangsheng, Hu, Chunhong, Liang, Houjie, Guo, Yabing, Wang, Jufeng, Yen, Chia-Jui, Lee, Victor Ho-Fun, Wang, Chunxiao, Widau, Ryan C., Zhang, Wanli, Liu, Junjun, Zhang, Qiang, Qin, Shukui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562926/ https://www.ncbi.nlm.nih.gov/pubmed/36247923 http://dx.doi.org/10.1016/j.eclinm.2022.101679

Ejemplares similares

Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non–Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2
por: Finn, Richard S, et al.
Publicado: (2022)

Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
por: Zhu, Andrew X., et al.
Publicado: (2021)

Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials
por: Llovet, Josep M., et al.
Publicado: (2022)

Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
por: Chau, Ian, et al.
Publicado: (2018)

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab
por: Reig, Maria, et al.
Publicado: (2020)

Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein
por: Gilabert, Marine, et al.
Publicado: (2018)

Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison
por: Trojan, Jörg, et al.
Publicado: (2021)

Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells
por: Taha, Amna Mohamed, et al.
Publicado: (2022)

Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials
por: Zhu, Andrew X, et al.
Publicado: (2020)

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)
por: Arkenau, Hendrik‐Tobias, et al.
Publicado: (2018)

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
por: Qin, Shukui, et al.
Publicado: (2021)

The Effectiveness of Hepatic Arterial Infusion Chemotherapy with 5-Fluorouracil/Cisplatin and Systemic Chemotherapy with Ramucirumab in Alpha-Fetoprotein-Producing Gastric Cancer with Multiple Liver Metastases
por: Doi, Yasuhiro, et al.
Publicado: (2018)

Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
por: Lee, Sangheun, et al.
Publicado: (2015)

α‐Fetoprotein fragment synergizes with sorafenib to inhibit hepatoma cell growth and migration and promote the apoptosis
por: Wang, Qiujiao, et al.
Publicado: (2022)

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018)

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial
por: Qin, Shukui, et al.
Publicado: (2023)

Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility
por: D’Alessandro, Rosalba, et al.
Publicado: (2019)

Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis
por: Park, Joon Oh, et al.
Publicado: (2016)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
por: Hsu, Po‐Yao, et al.
Publicado: (2021)

The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization
por: Liu, Lei, et al.
Publicado: (2016)

Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report
por: Xu, Su-Zhen, et al.
Publicado: (2022)

Ramucirumab: preclinical research and clinical development
por: Aprile, Giuseppe, et al.
Publicado: (2014)

The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs
por: Yang, Hongqiong, et al.
Publicado: (2021)

Efficacy of low dose capecitabine and sorafenib in patients with advanced alfa-fetoprotein secreting hepatocellular carcinoma: a 1 year experience
por: Hanafy, Amr Shaaban
Publicado: (2016)

Evaluation of sorafenib for advanced hepatocellular carcinoma with low α-fetoprotein in arrival time parametric imaging using contrast-enhanced ultrasonography
por: Shiozawa, Kazue, et al.
Publicado: (2016)

Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab
por: Fung, Andrea S., et al.
Publicado: (2020)

Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis
por: Chen, Jianxin, et al.
Publicado: (2021)

Clinical utility of ramucirumab in advanced gastric cancer
por: Chan, Matthew MK, et al.
Publicado: (2015)

Ramucirumab: A New Therapy for Advanced Gastric Cancer
por: Oholendt, Andrea Landgraf, et al.
Publicado: (2015)

Population pharmacokinetic meta‐analysis of ramucirumab in cancer patients
por: O'Brien, Lisa, et al.
Publicado: (2017)

Gastric perforation related to concurrent use of nintedanib and ramucirumab
por: Takahashi, Saeko, et al.
Publicado: (2018)

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
por: Gil-Delgado, Maria Angeles, et al.
Publicado: (2018)

Delayed Healing of Tooth Extraction Sockets with Ramucirumab Use
por: Iijima, Yosuke, et al.
Publicado: (2020)

Ramucirumab-Induced Hepatocellular Carcinoma Rupture and Gastrointestinal Perforation
por: Haider, Asim, et al.
Publicado: (2021)

Immunohistochemical Type Distinction of a‐Fetoprotein in Various a‐Fetoprotein‐secreting Tumors
por: Okamoto, Tsukasa, et al.
Publicado: (1993)

High HBV Load Weakens Predictive Effect of Serum miR-122 on Response to Sorafenib in Hepatocellular Carcinoma Patients
por: Zhang, Xiaomin, et al.
Publicado: (2021)

Inflammatory cytokines and alpha-fetoprotein concentrations for predicting survival in patients with hepatocellular carcinoma
por: Han, Xue, et al.
Publicado: (2019)

Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers
por: ElHalawani, Hesham, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ael5daeaiqm6co8p98pnkvqm81